*Among patients undergoing hemodialysis.
KDIGO=Kidney Disease: Improving Global Outcomes.
†Rhabdomyolysis and tumor lysis syndrome.
Modulated through intestinal absorption, bone turnover and mineralization, and renal regulation.
Parathyroid hormone (PTH), calcitriol, and fibroblast growth factor 23 (FGF23) also play a key regulatory role.3,4
GI=gastrointestinal (system); Ca=calcium; P=phosphate.
The capacity for phosphate filtration is reduced in the kidney of patients with CKD, leading to hyperphosphatemia.2-3
GFR=glomerular filtration rate.
‡An observational study of 1814 patients with CKD.
Management of phosphate levels for patients with CKD is important to avoid poor clinical outcomes. The KDIGO Guidelines offer recommendations for monitoring and managing levels towards the normal range.5,10
Reduce phosphate intake¶
¶Phosphate intake should not exceed 1000 mg/day.
Increase phosphate removal
Decrease intestinal absorption of phosphate
#When considering treatment for CKD-MBD
**For CKD stage G3a (mildly to moderately decreased GFR) to G5D (kidney failure).
††In adult patients with CKD
‡‡In adult patients with CKD.